Contrast-enhanced dual-energy ct of gastrointestinal stromal tumors: Is iodine-related attenuation a potential indicator of tumor response?

Investigative Radiology

Volumn 47, Issue 1, 2012, Pages 65-70

  Apfaltrer, Paul ^a   Meyer, Mathias ^a   Meier, Caroline ^a   Henzler, Thomas ^a   Barraza, John M ^b   Dinter, Dietmar J ^a   Hohenberger, Peter ^a   Schoepf, U Joseph ^b   Schoenberg, Stefan O ^a   Fink, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Dual energy CT; Gastrointestinal stromal tumors; RECIST; Response evaluation

Indexed keywords

IMATINIB; IOMEPROL; NILOTINIB; SUNITINIB;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SIZE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DRUG MONITORING; DRUG RESPONSE; DUAL ENERGY COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRIORITY JOURNAL;

EID: 84155163014     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31823003d2     Document Type: Article

References (34)

1. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007; 5(suppl 2):S1-S29; quiz S30.
2. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
3. Langer C, Gunawan B, Schuler P, et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg. 2003;90:332-339.
4. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-1134.
5. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760-1764.
6. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist. 2008;13(suppl 2):4-7.
7. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol. 2004;183:1619-1628.
8. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastro-intestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-1759.
9. Revheim ME, Winge-Main AK, Hagen G, et al. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol). 2011;23:339-343.
10. Reichardt P, Schneider U, Stroszczynski C, et al. Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate. J Clin Pathol. 2004;57:215-217.
11. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep. 2005;7:307-311.
12. Hong X, Choi H, Loyer EM, et al. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics. 2006;26:481-495.
13. Tawfik AM, Kerl JM, Bauer RW, et al. Dual-energy CT of head and neck cancer: average weighting of low-and high-voltage acquisitions to improve lesion delineation and image quality-initial clinical experience. Invest Radiol. 2011 May 13 [Epub ahead of print.]
14. Graser A, Johnson TR, Hecht EM, et al. Dual-energy CT in patients suspected of having renal masses: can virtual nonenhanced images replace true nonenhanced images? Radiology. 2009;252:433-440.
15. Neville AM, Gupta RT, Miller CM, et al. Detection of renal lesion enhancement with dual-energy multidetector CT. Radiology. 2011;259:173-183.
16. Sommer CM, Schwarzwaelder CB, Stiller W, et al. Iodine removal in intravenous dual-energy CT-cholangiography: is virtual non-enhanced imaging effective to replace true non-enhanced imaging? Eur J Radiol. 2011 Feb 23 [Epub ahead of print.]
17. Zhang LJ, Peng J, Wu SY, et al. Liver virtual non-enhanced CT with dual-source, dual-energy CT: a preliminary study. Eur Radiol. 2010;20:2257-2264.
18. Fletcher JG, Takahashi N, Hartman R, et al. Dual-energy and dual-source CT: is there a role in the abdomen and pelvis? Radiol Clin North Am. 2009;47: 41-57.
19. Yeh BM, Shepherd JA, Wang ZJ, et al. Dual-energy and low-kVp CT in the abdomen. Am J Roentgenol. 2009;193:47-54.
20. Lee SH, Lee JM, Kim KW, et al. Dual-energy computed tomography to assess tumor response to hepatic radiofrequency ablation: potential diagnostic value of virtual noncontrast images and iodine maps. Invest Radiol. 2011;46: 77-84.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
22. Le Cesne A, Van Glabbeke M, Verweij J, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. 2009;27:3969-3974.
23. Graser A, Johnson TR, Chandarana H, et al. Dual energy CT: preliminary observations and potential clinical applications in the abdomen. Eur Radiol. 2009;19:13-23.
24. Chandarana H, Godoy MC, Vlahos I, et al. Abdominal aorta: evaluation with dual-source dual-energy multidetector CT after endovascular repair of aneurysms-initial observations. Radiology. 2008;249:692-700.
25. Graser A, Becker CR, Staehler M, et al. Single-phase dual-energy CT allows for characterization of renal masses as benign or malignant. Invest Radiol. 2010;45:399-405.
26. Ende JF, Huda W, Ros PR, et al. Image mottle in abdominal CT. Invest Radiol. 1999;34:282-286.
27. Guimaraes LS, Fletcher JG, Harmsen WS, et al. Appropriate patient selection at abdominal dual-energy CT using 80 kV: relationship between patient size, image noise, and image quality. Radiology. 2010;257:732-742.
28. Huda W, Bushong SC. In x-ray computed tomography, technique factors should be selected appropriate to patient size. Med Phys. 2001;28:1543-1545.
29. Szucs-Farkas Z, Verdun FR, von Allmen G, et al. Effect of X-ray tube parameters, iodine concentration, and patient size on image quality in pulmonary computed tomography angiography: a chest-phantom-study. Invest Radiol. 2008;43:374-381.
30. Primak AN, Giraldo JC, Eusemann CD, et al. Dual-source dual-energy CT with additional tin filtration: dose and image quality evaluation in phantoms and in vivo. Am J Roentgenol. 2010;195:1164-1174.
31. Schlemmer M, Sourbron SP, Schinwald N, et al. Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy. Eur J Radiol. 2011;77:312-318.
32. Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. Am J Roentgenol. 2006;187:1267-1273.
33. De Giorgi U, Aliberti C, Benea G, et al. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2005;11:6171-6176.
34. Weininger M, Schoepf UJ, Ramachandra A, et al. Adenosine-stress dynamic real-time myocardial perfusion CT and adenosine-stress first-pass dual-energy myocardial perfusion CT for the assessment of acute chest pain: initial results. Eur J Radiol. 2010 Dec 29 [Epub ahead of print.]